UK-based pharmaceutical supply company, Sciensus, has announced that it has acquired the cancer patient support app, Vinehealth, with the aim of using data collected from the app to support what the company calls actionable insights.
The Vinehealth App is an oncology platform designed to allow users to report and track symptoms of disease progression in real time, whilst allowing that same data to be shared with clinicians. The app joins Sciensus’ roster of telehealth and remote patient monitoring apps including the company’s own InTouch app. It also adds further support for oncology patients to the company’s remit, which already covers more than 50 indications digitally.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSciensus believes that increased patient engagement with the app will generate actionable insights to support clinicians in providing optimal clinical decision-making and treatment management, but also gives the company a platform to expand into new regions as the app has been granted market authorisation by the US Food and Drug Administration (FDA), the Medicines and Healthcare products Regulatory Agency (MHRA), and the EU.
Darryn Gibson, CEO of Sciensus, said: “Vinehealth presents a rare and exciting opportunity to acquire a fast-growing, highly innovative business, which is transforming cancer patient outcomes and will significantly strengthen our digital insight offerings.”
A report published by GlobalData, detailed how in 2020 the overall market for telehealth apps stood at around $2bn, but by 2024 that figure is estimated to have risen to $5bn, with further growth projected into 2030 where it is estimated to hit $12bn dollars.
Vinehealth founders, Rayna Patel and Georgina Kirby added: “This deal marks an important milestone for Vinehealth. Uniting with Sciensus will extend our reach to patients by leveraging their patient network, and relationships with all the leading pharmaceutical companies and healthcare practitioners.”
Aside from the indication of oncology other telehealth apps designed to allow patients to monitor symptoms, such as Tilak Healthcare’s OdySight app have similarly seen success, with the app seeing positive results from a clinical trial designed to test the sight of macular degeneration patients.
